Tamoxifen--the treatment of choice. Why look for alternatives? by Baum, M.
British Joumal ofCancer (1998) 78(Supplement 4), 1-4
© 1998 Cancer Research Campaign
Tamoxifen - the treatment of choice. Why look for
alternatives?
M Baum
University College London Hospital, London, UK
Summary Tamoxifen is currently established as the endocrine treatment of choice in breast cancer. In advanced breast cancer, response
rates of up to 60% in women with oestrogen receptor (ER)-positive tumours have been reported. In early breast cancer, tamoxifen can
produce significant benefits, both statistically and clinically, in terms of reduction in relative risk of relapse or death in all patientsubgroups (i.e.
ER status, aged < or > 50 years) except premenopausal women with ER-negative tumours. The major benefit, however, is seen in women
over 50 years old with ER-positive tumours. The results of randomized trials suggest thatthe optimum duration oftamoxifen therapy is at least
5 years. Two large pragmatic trials (aTTom and ATLAS) are under way to determine whether additional benefit can be gained from continuing
tamoxifen treatment beyond 5 years. Recent data also suggest possible synergism between tamoxifen and chemotherapy in the treatment of
early breast cancer in post-menopausal women. Other benefits of tamoxifen treatment include reduction in the risk ofdeveloping contralateral
breast cancer. Included among the non-breast cancer benefits of tamoxifen are reduced risk of cardiovascular disease and protection against
bone loss in post-menopausal women. These benefits must be weighed against the possible increased incidence of endometrial cancer.
Notwithstanding its undoubted success, there is a need for agents to improve upon tamoxifen. Newer agents, such as the luteinizing
hormone-releasing hormone analogue goserelin and the new-generation aromatase inhibitors, such as anastrozole, will add new life to the
search for an improved endocrine therapy for early breast cancer.
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Tamoxifen therapy has undoubtedly been one of the greatest
success stories in the pharmacological management of breast
cancer. Tamoxifen's value forthis indication was discovered almost
accidentally about 30 years ago, and in the early 1970s the drug
was soon established as the treatment of choice for post-
menopausal women with breast cancer, replacing the then conven-
tional treatment with diethylstiboestrol. Tamoxifen has a good
tolerability profile, and serious side-effects are rare. The most
common adverse events reported are hotflushes, vaginal discharge,
irregular menses and endometrial changes. Less common adverse
events include tumour flare, visual disturbances, leucopenia,
ovarian cysts in premenopausal women and liver enzyme abnor-
malities. Despite this, withdrawal from tamoxifen treatment
because ofadverse events is below 5% in most patient series.
Using conventional Union Intemationale Contre Cancer (UICC)
criteria, tamoxifen produces an objective remission rate of about
30% in unselected cases of advanced breast cancer. If, however,
stable disease is accepted as a useful clinical end point and patients
with visceral disease or oestrogen receptor (ER)-negative disease
are excluded, the useful response rate rises to about 60%. The
median duration of response in these cases is about 2 years, but
eventually all patients will relapse and die (Jaiyesimi et al, 1995;
Baum, 1997; Powles, 1997). Tamoxifen gives comparable
response rates to other endocrine modalities (Table 1) (Rose and
Mouridsen, 1988). In view ofits side-effect profile in comparison
with these other agents (Muss, 1992), it is easy to understand why
tamoxifen was so rapidly accepted when it was introduced for the
management ofadvanced breast cancer.
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ADJUVANT THERAPY WITH TAMOXIFEN
Current status
The benefit of tamoxifen as adjuvant therapy after the surgical
treatment ofearly breast cancer is ofeven greater importance than
its benefit in advanced disease. The first trials foradjuvant therapy
were started in the late 1970s and the results were reported in the
early 1980s. Originally, the control groups were given no adjuvant
therapy and the treated groups received either 1 or 2 years of
tamoxifen treatment. The first trial to demonstrate a survival
advantage with adjuvant tamoxifen was the Nolvadex Adjuvant
Trial Organisation (NATO) study, published in 1983 (Nolvadex
Adjuvant Trial Organisation, 1983). Within a short time other
studies demonstrated a survival advantage with tamoxifen
prescribed for 2-5 years after surgery, and a meta-analysis ofadju-
vant tamoxifen trials conducted in 1990 demonstrated unequivo-
cally that adjuvant tamoxifen was associated with relative-risk
reductions for relapse and death of 25% and 17%, respectively,
over a 10-yearperiod (Early Breast CancerTrialists' Collaborative
Group, 1992).
In the last decade, knowledge of adjuvant tamoxifen has been
refined. The 1990 overview, published in 1992, showed that the
groups most likely to benefit were post-menopausal women with
ER-positive tumours, in whom up to 12% absolute improvement
in 10-year survival can be expected (Early Breast Cancer Trialists'
Collaborative Group, 1992). However, post-menopausal women
with ER-negative tumours and premenopausal women with ER-
positive tumours were also seen to benefit (Early Breast Cancer
Trialists' Collaborative Group, 1992).
The current status of tamoxifen in adjuvant therapy has been
confirmed following the 15-year world overview conducted in2 M Baum
Table 1 Efficacy of tamoxifen compared with other endocrine modalities for the treatment of advanced breast cancer (adapted from Rose
and Mouridsen, 1988)
Tamoxifen percentage Comparative
Number response (number of percentage response
of trials patients) (number of patients) Treatment modality
2 25 (81) 27 (79) Oophorectomy
1 35 (26) 52 (25) Adrenalectomy
6 27 (248) 28 (249) Oestrogens
3 26 (123) 18 (136) Androgens
12 34 (696) 35 (762) Progestins
2 33 (99) 32 (93) Aminoglutethimide (plus
hydrocortisone)
1995 (Early Breast Cancer Trialists' Collaborative Group, 1998).
Tamoxifen can produce significant benefits, both statistically and
clinically, in relative-risk reduction of relapse or death in all
subgroups. However, unlike the 1992 overview, the clinical
benefit observed did not extend to premenopausal women with
ER-negative tumours. The major advantage, however, is seen in
women over 50 years old with ER-positive tumours. Bearing in
mind that two-thirds of breast cancers occur in women over the
age of50 years and that about two-thirds ofthese are ER-positive,
a substantial number of patients stand to derive major benefits
from adjuvant tamoxifen treatment.
Duration of tamoxifen therapy
The optimum duration of tamoxifen therapy is still undetermined,
although more data have become available in recent years. It is
clear that 2 years of therapy is suboptimal, and that the optimum
duration may be at least 5 years. Based on current data, however, 5
years oftamoxifen can be considered a good standard oftreatment
(Current Trials Working Party of the Cancer Research Campaign
Breast Cancer Trials Group, 1996; Fisher et al, 1996; Swedish
Breast Cancer Cooperative Group, 1996). The Swedish Breast
Cancer Cooperative Group trial enrolled over 1700 patients in
each treatment arm, and compared 2 and 5 years of tamoxifen
therapy with a follow-up to 10 years (Swedish Breast Cancer
Cooperative Group, 1996). A highly significant difference in
event-free survival at 10 years was found, and a just significant
improvement in overall survival at 10 years for 5 years versus 2
years of treatment (Figure 1). The Cancer Research Campaign
Breast Cancer Trials Group also enrolled large numbers ofpatients
(over 1400 in each treatment arm). It found a significant advantage
for 5 years oftamoxifen therapy over2 years in terms ofevent-free
survival to 6 years, but no significant difference in overall survival
(Figure 2) (Current Trials Working Party of the Cancer Research
Campaign Breast Cancer Trials Group, 1996). The results in these
two data sets might seem slightly disappointing, but it must be
remembered that not all the patients in the 5-year arms of these
studies received tamoxifen for 5 years. The advantage may
become more apparent with longer follow-up and more patients in
the 5-year arm. Other studies have suggested that 5 years may be
the optimum duration oftreatment (Fisher et al, 1996).
Much uncertainty still remains concerning the optimum dura-
tion ofTamoxifen Treatment. Two large-scale trials, aTTom (adju-
vant Tamoxifen Treatment offer more?) and ATLAS (Adjuvant
Tamoxifen - Longer Against Shorter), have been designed to
address this problem (Peto, 1996). The aTTom trial has a simple
and pragmatic design. After at least 2 years of relapse-free adju-
vant tamoxifen therapy, the uncertainty principle applies: iffurther
tamoxifen is indicated, the patient is not eligible for inclusion in
the trial, whereas if it is uncertain whether the drug should be
continued the patient is randomized either to stop tamoxifen treat-
ment or to continue it for at least 3 years. The ATLAS trial has a
similar design. Again, the patients enrolled had received at least 2
years of relapse-free adjuvant tamoxifen therapy. The uncertainty
principle also applies in this trial: if there is uncertainty as to
whether tamoxifen should be continued, the patient is randomized
either to stop tamoxifen or to continue the drug for at least 5 years.
It is hoped that the results of these pragmatic trials with large
numbers ofpatients will define the optimum duration ofthe drug.
Synergism between tamoxifen and chemotherapy
Recent data suggest that some degree of synergism may be
achieved between tamoxifen and chemotherapy, which may
further improve the response to treatment in selected cases
(Tormey et al, 1996). Disease-free survival and overall survival at
5 years were compared in patients with ER-positive breast cancer
receiving tamoxifen alone, tamoxifen plus methotrexate and 5-
fluorouracil (MF), or tamoxifen plus cyclophosphamide and MF
(CMF) (Fisher et al, 1997). The disease-free survival rate at 5
years was 90% in the tamoxifen plus CMF group - significantly
better (P < 0.01) than that with tamoxifen alone (84%) (Table 2).
Protection against contralateral breast cancer
Tamoxifen is of proven value in reducing the risk of contralateral
breast cancer. The Early Breast Cancer Trialists' Collaborative
Group overview published in 1992 suggested that 5 years oftamox-
ifen treatment may reduce the relative risk of contralateral disease
by about 50% (Early Breast Cancer Trialists Collaborative Group,
1992). The 1995 world overview confirms this benefit (Early Breast
Cancer Trialists Collaborative Group, 1998). Based on these data,
large-scale trials are in progress in Europe and North America for
the prevention ofbreast cancer in womenjudged to be at high risk.
Beneficial and harmful side-effects of tamoxifen
Considerable research effort is throwing light on the mechanisms
ofresponse to and resistance to tamoxifen, which can no longer be
considered simply as an anti-oestrogen. In fact, the drug's agonist
properties may be responsible for some of its unanticipated bene-
fits and potential adverse effects.
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Figure 1 Effect of duration of treatment with tamoxifen (2 years vs 5 years)
on (A) event-free survival and (B) overall survival in women under 75 years
of age with early breast cancer in the Swedish Breast Cancer Cooperative
Group trial. Reproduced with permission from the Joumal of the National
Cancer Institute (Swedish Breast Cancer Cooperative Group, 1996)
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Figure 2 Effect of duration of treatment with tamoxifen (2 years vs 5 years)
on (A) event-free survival and (B) overall survival in post-menopausal
women with early breast cancer in the Cancer Research Campaign Breast
Cancer Trials Group trial. Reproduced with permission from the Joumalof
the National Cancer Institute (Current Trials Working Party of the Cancer
Research Campaign Breast Cancer Trials Group, 1996)
As an attenuated oestrogen, tamoxifen appears to protect the
myocardium, and to reduce the incidence of ischaemic heart
disease (Dewar et al, 1992; Love et al, 1994a) and the anticipated
loss of bone mineral density in post-menopausal women (Love et
al, 1992; Powles et al, 1996). Tamoxifen has been used in the treat-
ment of mastalgia (Bahamonde et al, 1997; Fentiman et al, 1988),
and beneficial effects on lipids (Love et al, 1994b; Bilimoria et al,
1996) have been demonstrated. At the same time, the agonist prop-
erties of tamoxifen are thought to be partly responsible for its
limited usefulness as an anti-oestrogen. There is some evidence that
experimental clones ofbreast cancer cells develop a dependence on
tamoxifen. Theoretically, the late failure of, or de novo resistance
to, adjuvant tamoxifen might be related to these observations
(DeFriend and Howell, 1994; Katzenellenbogen et al, 1997).
Tamoxifen has also been implicated in the increased incidence of
endometrial cancers that has been observed in some of the clinical
trials and reported in the meta-analysis (Assikis et al, 1996;
MacMahon, 1997). This relationship has not been observed in
British trials, however, and an ascertainment bias cannot be
excluded, as patients receiving tamoxifen are screened more inten-
sively for uterine abnormalities than those in the control groups. For
example, the gynaecological symptoms caused by tamoxifen are
often investigated by transvaginal ultrasonography, and endometrial
thickening is commonly reported. Biologically, the ultrasonographic
image does not always reflect endometrial thickening, but
commonly subendometrial cystic degeneration and oedema. As a
result, hysteroscopy is often performed, which might detect latent
endometrial cancer - in situ latent disease that would not have been
found if the woman had not had tamoxifen-induced gynaecological
symptoms. Furthermore, the one published study on endometrial
cancer screening in the normal population of women in the USA
(Koss et al, 1984) showed a prevalence not dissimilar to that
observed in a tamoxifen-treated group (Fisher et al, 1994).
Some worries have also been voiced about reports ofcrystalline
retinal deposits and other ocular toxicities. However, data from
prospective studies including the large adjuvant therapy trials
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Table 2 Beneficial effect of combining chemotherapy with tamoxifen in ER- Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of
positive early breast cancer (data from Fisher et al, 1997) early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:
1-15, 71-85
Disease-free survival Overall survival Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early
Treatment group at 5 years (%) at 5 years (%) breast cancer: an overview ofthe randomised trials. Lancet 351 (9114):
1451-1467
Tamoxifen alone 84 94 Fentiman IS, Calefti M, Hamed H, Chaudary MA (1988) Dosage and duration of
Tamoxifen plus MF 89* 96 tamoxifen treatment for mastalgia: a controlled trial. BrJSurg 75: 845-846
Tamoxifen plus CMF 90* 97 Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL and Cronin WM
(1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings
from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *P < 0.01 versus tamoxifen. [prior annotation incorrect]. J Natl Cancer Inst 86: 527-537
Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J,
indicate that the incidence oftamoxifen-related eye disease is very Redmond C, Fisher ER, Bowman DM,Deschenes L, Dimitrov NV, Margolese
tamoxifen-related Gdisease9very RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman Ml, Farrar W, low (Nayfield and Gorin, 1996). Evans J and Lickley HL (1996) Five versus more than five years oftamoxifen
therapy for breast cancer patients with negative lymph nodes and estrogen
CONCLUSIONS receptor-positive tumors. JNatl Cancer Inst 88: 1529-1542
Fisher B, Dignam J, DeCillis DL, et al (1997) The worth ofchemotherapy and
Since 1985, an overall reduction in breast cancer mortality has tamoxifen (TAM) over TAM alone in node-negative patients with estrogen-
taken place in the UK (Quinn and Allen, 1995). For the most part, receptor positive invasive breast cancer: first results from NSABP B-20
this must be attributed to the widespread adoption of adjuvant (abstract). Proc Am Soc Clin Oncol 16, la
systemic treatment, including tamoxifen therapy. The same fall in Forbes JF (1997) The control of breast cancer: the role of tamoxifen.Setmin Oncol mortamltyhasbea ent,seenli n theUSA.Itisessentiap l,however, not to 24(suppl. 1):(SI)5-19 mortality has been seen in the USA. It is essential, however, not to Jaiyesimi IA, Buzdar AU, Decker DA and Hortobagyi GN((1995) Use oftamoxifen
be complacent, and it is probable that we are close to recognizing forbreast cancer: twenty-eight years later [seecomments]. JCliii Onicol 13:
the limitations of this useful and relatively non-toxic agent (Quinn 513-529
and Allen, 1995; Forbes, 1997). The need for new drugs that will Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W,
replaceorimproveon tamoxifen is self-evident, and the potential J'anickeF, Njordenskold B and Forbes JF (1995) A randomised study to
relmitaceons
or
d improv e
on
effects have been described above.
compare the effect ofthe luteinising hormonereleasing hormone (LHRH)
limitations and possible adverse effects have been described above, analogue goserelin with orwithouttamoxifen in pre- and perimenopausal
It is possible that the luteinizing hormone-releasing hormone patients with advanced breast cancer. EurJCancer 31A: 137-142
analogue, goserelin (Jonat et al, 1995) and the new generation of Katzenellenbogen BS, Montano MM, Ekena K, Herman ME and Mclnerney EM
oral aromatase inhibitors, such as anastrozole (Buzdar et al, 1996, (1997) William L. Maguire Memorial Lecture. Antiestrogens: mechanisms of
action and resistance in breast cancer. Breast CancerRes Treat 44: 23-38 1997; Anonymous, 1997), will add new life to the search for the Koss LG, Schreiber K, OberlanderSG, Moussouris HF and Lesser M (1984)
ideal endocrine therapy for early breast cancer. With the establish- Detection ofendometrial carcinoma and hyperplasia in asymptomatic women.
ment of large-scale, multicentre collaborative groups and the ObstetGynecol64: 1-11
modern will for pan-European cooperation, it seems probable that Love RR, Mazess RB, Barden HS, et al (1992) Effects oftamoxifen on bone mineral
the efficacy and utility of these agents will be established in less density in postmenopausal women with breast cancer. NEngl J Med 326:
timeeffiancyttook to apprecia these valuentsofll tamoxife n. e less852-856
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